Novavax (FRA:NVV1) Cyclically Adjusted Revenue per Share: €4.87 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:NVV1 Novavax Inc FRA:NVV1
51 GF Score
Price €8.12
GF Value €2.74
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Novavax Cyclically Adjusted Revenue per Share?

Novavax FRA:NVV1 +9.43% 51 Cyclically Adjusted Revenue per Share is €4.87 as of Jun. 2026. GuruFocus rates FRA:NVV1 with a GF Score™ of 51/100 and a GF Value™ of €2.74 (Significantly Overvalued). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Novavax's adjusted revenue per share for the three months ended in Jun. 2026 was €0.299. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €4.87 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Novavax's average Cyclically Adjusted Revenue Growth Rate was 4.50% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 7.60% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 20.90% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 14.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Novavax was 28.80% per year. The lowest was -31.60% per year. And the median was 2.45% per year.

As of today (2026-08-26), Novavax's current stock price is €8.12. Novavax's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was €4.87. Novavax's Cyclically Adjusted PS Ratio of today is 1.67.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Novavax was 130.13. The lowest was 0.82. And the median was 6.63.


Novavax  (FRA:NVV1) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Novavax's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=8.12/4.87
=1.67

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Novavax was 130.13. The lowest was 0.82. And the median was 6.63.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Novavax Cyclically Adjusted Revenue per Share Related Terms


Novavax Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Novavax's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novavax Cyclically Adjusted Revenue per Share Chart

Novavax Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.25 3.77 4.42 4.86 4.60

Novavax Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.64 4.58 4.60 4.71 4.87

FRA:NVV1 vs JBIO, AVLN, TRAX: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, Novavax's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novavax Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Novavax's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Novavax's Cyclically Adjusted PS Ratio falls into.


FRA:NVV1
51GF Score
Novavax Inc FRA:NVV1
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Novavax Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Novavax's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.299/333.9520*333.9520
=0.299

Current CPI (Jun. 2026) = 333.9520.

Novavax Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 0.212 241.428 0.293
201612 0.377 241.432 0.521
201703 0.387 243.801 0.530
201706 0.423 244.955 0.577
201709 0.473 246.819 0.640
201712 0.556 246.524 0.753
201803 0.465 249.554 0.622
201806 0.491 251.989 0.651
201809 0.347 252.439 0.459
201812 0.281 251.233 0.374
201903 0.172 254.202 0.226
201906 0.127 256.143 0.166
201909 0.094 256.759 0.122
201912 0.282 256.974 0.366
202003 0.069 258.115 0.089
202006 0.538 257.797 0.697
202009 2.166 260.280 2.779
202012 -2.169 260.474 -2.781
202103 5.144 264.877 6.485
202106 3.337 271.696 4.102
202109 2.034 274.310 2.476
202112 -8.495 278.802 -10.175
202203 6.803 287.504 7.902
202206 2.251 296.311 2.537
202209 8.107 296.808 9.122
202212 3.403 296.797 3.829
202303 -0.070 301.836 -0.077
202306 3.764 305.109 4.120
202309 0.200 307.789 0.217
202312 1.875 306.746 2.041
202403 0.617 312.332 0.660
202406 2.327 314.175 2.473
202409 0.476 315.301 0.504
202412 0.526 315.605 0.557
202503 3.472 319.799 3.626
202506 1.170 322.561 1.211
202509 0.370 324.800 0.380
202512 0.669 324.054 0.689
202603 0.739 330.213 0.747
202606 0.299 333.952 0.299

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €4.87 mean?
Novavax (FRA:NVV1) has a Cyclically Adjusted Revenue per Share of €4.87 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Novavax and its competitors.
Is Novavax's Cyclically Adjusted Revenue per Share too high?
Novavax's current Cyclically Adjusted Revenue per Share is €4.87. Overall, Novavax has a GF Score™ of 51/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Novavax's Cyclically Adjusted Revenue per Share compare to JBIO and AVLN?
Novavax's Cyclically Adjusted Revenue per Share of €4.87 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Novavax and its competitors. Novavax's current Cyclically Adjusted Revenue per Share is €4.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novavax stock overvalued right now?
Based on GuruFocus' analysis, Novavax (FRA:NVV1) is currently considered Significantly Overvalued. The stock's GF Value™ is €2.74, compared to a current price of €8.12 — trading 196.4% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is €4.87. Novavax's overall GF Score™ is 51/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Novavax (FRA:NVV1), the current Cyclically Adjusted Revenue per Share is €4.87 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Novavax (FRA:NVV1) Overvalued in 2026?

Based on GuruFocus' analysis, Novavax stock appears to be overvalued. The current stock price of €8.12 is trading 196.4% above its estimated GF Value™ of €2.74. GuruFocus considers Novavax to be Significantly Overvalued.

Key valuation signals for FRA:NVV1:

  • Cyclically Adjusted Revenue per Share: €4.87
  • GF Value™: €2.74 vs. price of €8.12 (196.4% above fair value)
  • GF Score™: 51/100 with 6 warning signs

No single metric tells the full story. See the FRA:NVV1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Novavax Business Description

Address 21 Firstfield Road, Gaithersburg, MD, USA, 20878
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.
51GF Score

Get the complete analysis for FRA:NVV1

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€8.12
Price
€2.74
GF Value